NCT00856050已完成2 期
Phase 2 Clinical Study of Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- Progression Free Survival Rate at 12 Weeks
研究概览
简要总结
The purpose of this research study is to determine if letrozole is effective at controlling the growth or spread of estrogen and/or progesterone receptor positive uterine leiomyosarcoma. This drug has been used in research studies for other cancers and is currently approved by the FDA for use in breast cancer. Because letrozole lowers hormone levels in the body, it may be helpful to control tumors that express hormone receptors ( ER/PR).
详细描述
- Participants will take letrozole orally once a day. During the research study the following tests and procedures will be performed:
- Visit 1 (Day 1): physical examination, vital signs and blood work
- Visit 2 (Day 43): physical examination, vital signs, blood work, CT or MRI scan
- Visit 3 (Day 85): physical examination, vital signs, blood work, CT or MRI scan
- Participants will remain on the study drug as long as they do not have any serious sife effect and their disease does not get worse
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed, advanced estrogen (ER)/progesterone receptor (PR) positive leiomyosarcoma of uterine origin, for which standard multi-modality curative therapies do not exist or are no longer effective
- •Patients must be postmenopausal. Postmenopausal is defined as any of the following: 1)Bilateral oophorectomy 2) 60 years of age or older 3)Younger than 60 AND amenorrheic for 12 months or more AND follicle stimulating hormone (FSH) and estradiol (E2) within postmenopausal range 4)Ovarian ablation radiotherapy confirmed by FSH and estradiol (E2) level in the postmenopausal range
- •Evidence of ER and/or PR positivity, either in primary or secondary tumor tissue
- •Measurable disease outside of a prior irradiated area as defined by RECIST guidelines. A lesion in a previously irradiated area is not eligible for measurable diseae unless there is objective evidence of progression of the lesion prior to study enrollment
- •18 years of age or older
- •Life expectancy of 3 months or more
- •ECOG Performance Status 0, 1, or 2
- •No limit to number of prior chemotherapies or biologics
- •Normal organ function as outlined in the protocol
- •Resolution of clinically significant toxicities related to prior therapies
排除标准
- •Pre-menopausal women
- •Participants who have had systemic anti-cancer therapy within 3 weeks of study entry (8 weeks for nitrosoureas or mitomycin C)
- •Palliative radiotherapy within 2 weeks of study entry
- •Major surgery within 2 weeks of study entry
- •Prior hormonal therapy for the treatment of uterine leiomyosarcoma (prior hormone replacement therapy is allowed)
- •Participants may not be receiving any other concomitant investigational agents
- •Uncontrolled brain or central nervous system metastases
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to letrozole
- •Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Individuals with a history of a different malignancy, other than cervical cancer in situ, basal cell or squamous cell carcinoma of the skin, are ineligible, except if they have been disease-free for at least 5 years, and are deemed by the investigator to be at low risk for recurrence of that malignancy OR other primary malignancy is neither currently clinically significant nor requiring active intervention
研究组 & 干预措施
letrozole
Experimental
single arm trial - all patients received letrozole 2.5mg by mouth per day
干预措施: letrozole (Drug)
结局指标
主要结局
Progression Free Survival Rate at 12 Weeks
时间窗: 12 weeks
Data below are reported as progression free rate (%).
次要结局
未报告次要终点
研究者
Suzanne George, MD
Principal Investigator
Dana-Farber Cancer Institute
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors.Luteinised Follicular CystNCT06244745IVI Madrid152
已完成
4 期
Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSSOvarian Hyperstimulation SyndromeNCT02670304First Affiliated Hospital, Sun Yat-Sen University100
已完成
2 期
Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast CancerPostmenopausal Women With Advanced Breast CancerNCT00237211Novartis Pharmaceuticals31
撤回
2 期
Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal CancerFallopian Tube CancerPeritoneal CancerOvarian CancerNCT00634894M.D. Anderson Cancer Center
已完成
2 期
Evaluation of efficacy of Letrozole on the duration and severity of Ovarian hyperstimulation syndromeIRCT20141008019464N2Kerman University of Medical Sciences40